e-learning
resources
Munich 2014
Sunday, 07.09.2014
Asthma and COPD devices and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Holding chamber (Spacer) - A potential harbor of pathogenic bacteria
A. Agrawal, G. Nair, A. Uppe, U. Baby (Navi Mumbai, India)
Source:
International Congress 2014 – Asthma and COPD devices and treatments
Session:
Asthma and COPD devices and treatments
Session type:
Thematic Poster Session
Number:
914
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Agrawal, G. Nair, A. Uppe, U. Baby (Navi Mumbai, India). Holding chamber (Spacer) - A potential harbor of pathogenic bacteria. Eur Respir J 2014; 44: Suppl. 58, 914
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Development of a human COPD model-on-a-chip to mimic disease exacerbation (a small airway-on-a-chip model)
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Bacterial resistance induction with prophylactic antibiotics in COPD
Source: International Congress 2014 – COPD markers
Year: 2014
Distribution and outcomes of the new Spanish phenotype-based guideline for COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Airway glucose in COPD exacerbations
Source: International Congress 2016 – Clinical and microbiological aspects of infections in COPD patients
Year: 2016
Targeted lung denervation in the healthy sheep model - A potential treatment for COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Effectiveness of a comprehensive management program of fragile COPD patients
Source: International Congress 2014 – Phenotyping and monitoring asthma and COPD
Year: 2014
Decametoxine efficiency in the treatment of infectious exacerbation of asthma
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Identification of nasal virus infection in patients with COPD exacerbations
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Value of adding treatment with lyophilized bacterial lysates in reducing COPD exacerbations in COPD patients risk group C and D
Source: International Congress 2014 – Non inflammatory monitoring of airway diseases
Year: 2014
Clinical cure rates in patients treated with azithromycin (AZ) for lower respiratory infections (LRTI) caused by AZ-susceptible (AZ-S) and AZ-resistant (AZ-R) organisms: Analysis of phase 3 clinical trials
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Relationship between COPD characteristics and airway bacterial load measured using 16S qPCR
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Association between qPCR bacterial load and airway inflammation in COPD
Source: Annual Congress 2013 –COPD: new markers of diseases
Year: 2013
Implications of under treatment of stable COPD (SAVING study)
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Inspiratory flow resistance of marketed dry powder inhalers (DPI)
Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases
Year: 2014
Gold vs GesEPOC: Are they different?
Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations
Year: 2013
Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Evaluation of the use of CAT in COPD. Results of On-Sint study
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014
Impact of chronic obstructive pulmonary disease (COPD) and patients' absence from work in Greece - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept